ArticleEmerging infectious diseases2022
Neisseria gonorrhoeae FC428 Subclone, Vietnam, 2019-2020.
Article in Emerging infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Abolishing PorB-induced mitophagy enhances gonococcal outer membrane vesicle vaccine efficacy.Emerging microbes & infections · 2026Article
- Assessing N. gonorrhoeae prevalence and testing capacity for new treatment rollout: a scoping review for Cambodia, Thailand, Vietnam and South Africa.BMC infectious diseases · 2026Article
- Stepwise evolution and clonal enrichment of gepotidacin resistance inAntimicrobial agents and chemotherapy · 2026Article
- Trends in population structure, antimicrobial susceptibility and resistance determinants ofJAC-antimicrobial resistance · 2026Article
- Detection of non-travel-associated, ceftriaxone non-susceptibleCanada communicable disease report = Releve des maladies transmissibles au Canada · 2025Article
- High Prevalence of Ceftriaxone-Resistant Neisseria gonorrhoeae in Hanoi, Vietnam, 2023-2024.The Journal of infectious diseases · 2025Article
- Genetic identification of mutations and MLST types associated with decreased susceptibility to ceftriaxone inFrontiers in microbiology · 2025Article
- Multigeographic clinical assessment of a molecular diagnostic assay for detection of key codons to predict decreased susceptibility or resistance to cephalosporins inAntimicrobial agents and chemotherapy · 2024Article
- Ceftriaxone-Resistant Gonorrhea - China, 2022.MMWR. Morbidity and mortality weekly report · 2024Article
- Th1-polarized MtrE-based gonococcal vaccines display prophylactic and therapeutic efficacy.Emerging microbes & infections · 2023Article
- High-level in vitro resistance to gentamicin acquired in a stepwise manner in Neisseria gonorrhoeae.The Journal of antimicrobial chemotherapy · 2023Article
- Increase in Multidrug ResistantInfection and drug resistance · 2023Article
- Antimicrobial Activity of Auranofin, Cannabidivarin, and Tolfenamic Acid against Multidrug-Resistant Neisseria gonorrhoeae.Microbiology spectrum · 2022Article
- Detection of 10 cases of ceftriaxone-resistantEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2022Article
- Molecular Mechanisms of Drug Resistance and Epidemiology of Multidrug-Resistant Variants ofInternational journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
Among 114 clinical Neisseria gonorrhoeae isolates collected in Vietnam during 2019-2020, we detected 15 of subclone sequence type 13871 of the FC428 clonal complex. Fourteen sequence type 13871 isolates with mosaic penA allele 60.001 were ceftriaxone or cefixime nonsusceptible, and 3/14 were azithromycin nonsusceptible. Emergence of this subclone threatens treatment effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.